Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd.-PIPELINE

Pipelines

Our core flagship pipelines

• We are the ARCHITECTS of Combination Cures™ — Powered by a Dual-Technology Backbone: siRNA+Antibody.

• World-leading siRNA and Antibody to shut down HBV replication, and reboot the immune defense.

Phase II trials underway- POC Data Rivaling The BEST

Overview

In the clinical research phase, siRNA and hepatitis B neutralizing antibody therapies have entered phase II clinical trials. The two-drug combination therapy, a global leader in development, aims to achieve a functional cure for hepatitis B.